DK2222707T3 - Monoklonale anti-faktor-XI-antistoffer og fremgangsmåde til anvendelse deraf - Google Patents
Monoklonale anti-faktor-XI-antistoffer og fremgangsmåde til anvendelse deraf Download PDFInfo
- Publication number
- DK2222707T3 DK2222707T3 DK08852770.0T DK08852770T DK2222707T3 DK 2222707 T3 DK2222707 T3 DK 2222707T3 DK 08852770 T DK08852770 T DK 08852770T DK 2222707 T3 DK2222707 T3 DK 2222707T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- factor
- amino acid
- fxi
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (16)
1. Oprenset anti-faktor-XI (FXI)-antistof eller biologisk aktivt fragment deraf, der specifikt binder humant FXI, beskrevet i SEQ ID NO: 1, hvor antistoffet eller det biologisk aktive fragment deraf omfatter seks komplementaritetsbestemmende region (CDR)-regioner, hvor CDR-regionerne har aminosyrese-kvensen ifølge SEQ ID NO: 10, 11, 12,13, 14 og 15.
2. Antistof ifølge krav 1, hvor antistoffet omfatter en immunoglobulin-tungkæde, omfattende en aminosyresekvens, der er valgt fra gruppen bestående af: a) en aminosyresekvens ifølge SEQ ID NO: 3 eller 7; og b) en aminosyresekvens, der har mindst 85% sekvensidentitet med aminosy-resekvensen ifølge SEQ ID NO: 3 eller 7; og/eller hvor antistoffet omfatter en immunoglobulin-letkæde, omfattende en aminosyresekvens, der er valgt fra gruppen bestående af: a) en aminosyresekvens ifølge SEQ ID NO: 5 eller 9; og b) en aminosyresekvens, der har mindst 85% sekvensidentitet med aminosy-resekvensen ifølge SEQ ID NO: 5 eller 9.
3. Antistof eller fragment ifølge krav 1 eller 2 til anvendelse i en fremgangsmåde til behandling af et individ til inhibering af trombose uden at påvirke hæmostase negativt, hvilken fremgangsmåde omfatter at administrere en virksom dosis af antistoffet eller fragmentet til individet.
4. Antistof eller fragment til anvendelse ifølge krav 3, hvor trombose er forbundet med myokardieinfarkt, ustabil angina, aterieflimren, slagtilfælde, nyreskade, lungeemboli, dyb venetrombose, perkutan transluminal koronar an-gioplastik, dissemineret intravaskulær koagulation, blodforgiftning, kunstige organer, shunts eller prostese.
5. Antistof eller fragment til anvendelse ifølge krav 3, hvor fremgangsmåden omfatter at administrere antistoffet i kombination med et anti-trombosemiddel.
6. Antistof eller fragment til anvendelse ifølge krav 5, hvor anti-trombosemidlet er en direkte eller indirekte trombin-inhibitor, en faktor X-inhibitor, en faktor IX-inhibitor, en faktor Xll-inhibitor, en faktor V-inhibitor, en faktor Vlll-inhibitor, en faktor Xlll-inhibitor, en faktor Vll-inhibitor, en vævsfaktorinhibitor, et profibrinolytisk middel, et fibrinolytisk eller fibrinogenolytisk middel, en carboxypeptidase B-inhibitor, en blodplade-inhibitor, et middel, der selektivt reducerer blodpladeantallet, eller en faktor Xl-inhibitor.
7. Antistof eller fragment ifølge krav 1 eller krav 2 til anvendelse i en fremgangsmåde til behandling af metastatisk cancer hos et individ, hvilken fremgangsmåde omfatter at administrere en terapeutisk virksom dosis af antistoffet eller fragmentet til et individ.
8. Antistof eller fragment ifølge krav 1 eller 2 til anvendelse i en fremgangsmåde til behandling af en akut inflammatorisk reaktion hos et individ, hvilken fremgangsmåde omfatter at administrere en terapeutisk virksom dosis af antistoffet eller fragmentet til individet.
9. Antistof eller fragment til anvendelse ifølge et af kravene 3 til 8, hvor individet er et menneske.
10. Antistof eller fragment til anvendelse ifølge et af kravene 3 til 9, hvor antistoffet eller fragmentet i fremgangsmåden administreres til individet: (i) i en enkelt dosis på 0,01 mg/kg til 10 mg/kg; eller (ii) i en enkelt dosis på 2 mg/kg.
11. Antistof eller fragment til anvendelse ifølge et af kravene 3 til 10, hvor antistoffet eller fragmentet i fremgangsmåden administreres til individet via systemisk, topisk, parenteral eller enteral administration.
12. Farmaceutisk sammensætning omfattende et antistof eller fragment ifølge krav 1 eller 2 og en farmaceutisk acceptabel bærer, og hvor den farmaceutiske sammensætning eventuelt er formuleret til: (i) øjeblikkelig frigivelse af antistoffet eller fragmentet; eller (ii) kontrolleret frigivelse af antistoffet eller fragmentet.
13. Isoleret polynukleotid, hvor polynukleotidet omfatter en nukleinsyre, der koder for et antistof, omfattende: (i) en immunoglobulin-tungkæde, hvor immunoglobulin-tungkæden omfatter en aminosyresekvens, der er valgt fra gruppen bestående af: a) en aminosyresekvens ifølge SEQ ID NO: 3 eller 7; og b) en aminosyresekvens, der har mindst 85% sekvensidentitet med aminosy-resekvensen ifølge SEQ ID NO: 3 eller 7, og omfattende komplementaritetsbestemmende region (CDR)-regioner, hvor CDR-regionerne har aminosyre-sekvensen ifølge SEQ ID NO: 10,11 og 12; og (ii) en immunoglobulin-letkæde, hvor immunoglobulin-letkæden omfatter en aminosyresekvens, der er valgt fra gruppen bestående af: a) en aminosyresekvens ifølge SEQ ID NO: 5 eller 9; og b) en aminosyresekvens, der har mindst 85% sekvensidentitet med aminosy-resekvensen ifølge SEQ ID NO: 5 eller 9, og omfattende komplementaritetsbestemmende region (CDR)-regioner, hvor CDR-regionerne har aminosyre-sekvensen ifølge SEQ ID NO: 13, 14 og 15.
14. Isoleret polynukleotid ifølge krav 13, omfattende: (i) en polynukleotidsekvens, der er valgt fra gruppen bestående af: a) en polynukleotidsekvens ifølge SEQ ID NO: 2 eller 6; og b) en polynukleotidsekvens med mindst 85% sekvensidentitet med polynu-kleotidsekvensen ifølge SEQ ID NO: 2 eller 6; og (ii) en polynukleotidsekvens, der er valgt fra gruppen bestående af: a) en polynukleotidsekvens ifølge SEQ ID NO: 4 eller 8; og b) en polynukleotidsekvens med mindst 85% sekvensidentitet med polynu-kleotidsekvensen ifølge SEQ ID NO: 4 eller 8.
15. Vektor omfattende polynukleotidet ifølge krav 13 eller 14, hvor polynukleotidet eventuelt er funktionsmæssigt forbundet med en promoter.
16. Værtscelle omfattende: (i) polynukleotidet ifølge krav 13 eller 14; eller (ii) vektoren ifølge krav 15.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98952307P | 2007-11-21 | 2007-11-21 | |
| PCT/US2008/084336 WO2009067660A2 (en) | 2007-11-21 | 2008-11-21 | Anti-factor xi monoclonal antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2222707T3 true DK2222707T3 (da) | 2016-04-11 |
Family
ID=40568500
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15189714T DK3002298T3 (da) | 2007-11-21 | 2008-11-21 | Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf |
| DK08852770.0T DK2222707T3 (da) | 2007-11-21 | 2008-11-21 | Monoklonale anti-faktor-XI-antistoffer og fremgangsmåde til anvendelse deraf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15189714T DK3002298T3 (da) | 2007-11-21 | 2008-11-21 | Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US8236316B2 (da) |
| EP (2) | EP3002298B1 (da) |
| JP (1) | JP2011504371A (da) |
| AU (1) | AU2008326348B2 (da) |
| CA (1) | CA2705851C (da) |
| CY (1) | CY1122270T1 (da) |
| DK (2) | DK3002298T3 (da) |
| ES (2) | ES2755376T3 (da) |
| HK (1) | HK1223114A1 (da) |
| HR (1) | HRP20191999T1 (da) |
| HU (1) | HUE046564T2 (da) |
| LT (1) | LT3002298T (da) |
| PL (1) | PL3002298T3 (da) |
| PT (1) | PT3002298T (da) |
| SI (1) | SI3002298T1 (da) |
| WO (1) | WO2009067660A2 (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2755376T3 (es) * | 2007-11-21 | 2020-04-22 | Univ Oregon Health & Science | Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos |
| EP2297207B1 (en) * | 2008-06-19 | 2018-10-03 | Prothix BV | Use of anti-factor xi antibodies for prevention or treatment of thrombus formation |
| MX2011004097A (es) | 2008-10-15 | 2011-07-28 | Isis Pharmaceuticals Inc | Modulacion de la expresion del factor 11. |
| ES2720594T3 (es) | 2008-12-18 | 2019-07-23 | Univ Oregon Health & Science | Anticuerpos anti-fXI y métodos de uso |
| US20120083522A1 (en) * | 2009-04-15 | 2012-04-05 | Isis Pharmaceuitcals, Inc. | Modulation of inflammatory responses by factor xi |
| CA2976671C (en) * | 2010-03-01 | 2021-01-12 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| WO2012120128A1 (en) * | 2011-03-09 | 2012-09-13 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| ES2698950T3 (es) * | 2012-05-10 | 2019-02-06 | Bayer Pharma AG | Anticuerpos capaces de unirse al Factor XI de coagulación y/o a su forma activada, Factor XIa, y usos de los mismos |
| US9574013B2 (en) | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
| MX2015009914A (es) * | 2013-02-01 | 2015-09-25 | Becton Dickinson Co | Dispositivos de recogida de sangre que contienen aditivos de inhibicion de la via de contacto. |
| AU2014224599B2 (en) | 2013-03-08 | 2018-11-08 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| CA2957219A1 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
| US9988443B2 (en) | 2014-08-07 | 2018-06-05 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| EP3325010B1 (en) * | 2015-07-23 | 2023-06-21 | The Regents of The University of California | Antibodies to coagulation factor xia and uses thereof |
| CA3010224A1 (en) | 2016-01-22 | 2017-07-27 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| AU2017236063B2 (en) * | 2016-03-23 | 2024-06-13 | Prothix Bv | Monoclonal antibodies against the active site of factor XI and uses thereof |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| EA201892716A1 (ru) * | 2016-06-14 | 2019-05-31 | Мерк Шарп И Доум Корп. | Антитела к фактору свертывания xi |
| EP3293593B1 (en) * | 2016-09-12 | 2019-03-20 | Sandvik Intellectual Property AB | Method for estimating error propagation |
| PE20191319A1 (es) | 2016-09-20 | 2019-09-24 | Bayer Pharma AG | Anticuerpos novedosos contra el factor xi y sus usos |
| KR102616666B1 (ko) | 2016-12-23 | 2023-12-27 | 노파르티스 아게 | 인자 xi 항체 및 사용 방법 |
| CN118320078A (zh) * | 2016-12-23 | 2024-07-12 | 诺华股份有限公司 | 采用抗因子XI/XIa抗体治疗的方法 |
| US11958911B2 (en) | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
| CN108409863B (zh) * | 2017-02-10 | 2023-09-26 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| KR20200087236A (ko) * | 2017-11-22 | 2020-07-20 | 노파르티스 아게 | 항-인자 XI/XIa 항체에 대한 반전 결합제 및 이의 용도 |
| WO2019217450A1 (en) * | 2018-05-08 | 2019-11-14 | Rhode Island Hospital | Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications |
| MX2020011913A (es) | 2018-05-09 | 2021-01-29 | Ionis Pharmaceuticals Inc | Compuestos y metodos para la reduccion de la expresion de fxi. |
| BR112021002472A2 (pt) * | 2018-08-09 | 2021-07-27 | Shanghai Benemae Pharmaceutical Corporation | anticorpos antifator xi |
| AU2021302199A1 (en) * | 2020-07-03 | 2023-02-23 | Suzhou Alphamab Co., Ltd. | Coagulation factor XI (FXI) binding protein |
| WO2024141099A1 (zh) * | 2022-12-30 | 2024-07-04 | 甘李药业股份有限公司 | 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| US20030235587A1 (en) | 1998-08-07 | 2003-12-25 | Feuerstein Giora Z. | Anticoagulant agents useful in treatment of thrombosis |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6623960B1 (en) * | 1999-02-12 | 2003-09-23 | The United States Of America As Represented By The Department Of Health And Human Services | Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19 |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| KR20030034071A (ko) * | 2000-05-15 | 2003-05-01 | 스미스클라인 비참 코포레이션 | 항혈전제 |
| US7858559B2 (en) | 2000-11-17 | 2010-12-28 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20080138837A1 (en) * | 2004-07-19 | 2008-06-12 | Robert Greenfield | Methods and kits for detecting and measuring ADAMTS13/FXI complexes |
| EP2465872A3 (en) * | 2004-10-25 | 2012-12-19 | Merck Sharp & Dohme Corporation | Anti-ADDL antibodies and uses thereof |
| US7859456B2 (en) | 2006-10-10 | 2010-12-28 | Sirf Technology Holdings, Inc. | Method of mixed data assisted and non data assisted navigation signal acquisition, tracking and reacquisition |
| MX2009011500A (es) * | 2007-04-23 | 2010-01-29 | Schering Corp | Anticuerpos anti-mdl-1. |
| ES2755376T3 (es) | 2007-11-21 | 2020-04-22 | Univ Oregon Health & Science | Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos |
| EP2297207B1 (en) | 2008-06-19 | 2018-10-03 | Prothix BV | Use of anti-factor xi antibodies for prevention or treatment of thrombus formation |
| US8741910B2 (en) | 2008-11-25 | 2014-06-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| ES2564503T3 (es) | 2010-05-27 | 2016-03-23 | Merck Sharp & Dohme Corp. | Activadores de la guanilato-ciclasa soluble |
| CA2803688A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| CN103097387B (zh) | 2010-07-09 | 2016-11-02 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| JP6005134B2 (ja) | 2011-04-21 | 2016-10-12 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | フルオロアルキル置換ピラゾロピリジンおよびその使用 |
| CN103649093B (zh) | 2011-05-06 | 2017-07-07 | 拜耳知识产权有限责任公司 | 取代的咪唑并吡啶和咪唑并哒嗪及其用途 |
| MX359032B (es) | 2011-09-01 | 2018-09-12 | Hoffmann La Roche | Inhibidores de pirrolopirazina cinasa. |
| CA2847075A1 (en) | 2011-09-02 | 2013-03-07 | Bayer Intellectual Property Gmbh | Substituted annellated pyrimidine and the use thereof |
| ES2698950T3 (es) | 2012-05-10 | 2019-02-06 | Bayer Pharma AG | Anticuerpos capaces de unirse al Factor XI de coagulación y/o a su forma activada, Factor XIa, y usos de los mismos |
-
2008
- 2008-11-21 ES ES15189714T patent/ES2755376T3/es active Active
- 2008-11-21 EP EP15189714.7A patent/EP3002298B1/en not_active Revoked
- 2008-11-21 PT PT151897147T patent/PT3002298T/pt unknown
- 2008-11-21 HU HUE15189714A patent/HUE046564T2/hu unknown
- 2008-11-21 EP EP08852770.0A patent/EP2222707B1/en not_active Not-in-force
- 2008-11-21 JP JP2010535088A patent/JP2011504371A/ja not_active Withdrawn
- 2008-11-21 AU AU2008326348A patent/AU2008326348B2/en not_active Ceased
- 2008-11-21 PL PL15189714T patent/PL3002298T3/pl unknown
- 2008-11-21 DK DK15189714T patent/DK3002298T3/da active
- 2008-11-21 WO PCT/US2008/084336 patent/WO2009067660A2/en active Application Filing
- 2008-11-21 CA CA2705851A patent/CA2705851C/en not_active Expired - Fee Related
- 2008-11-21 SI SI200832100T patent/SI3002298T1/sl unknown
- 2008-11-21 US US12/744,037 patent/US8236316B2/en active Active
- 2008-11-21 ES ES08852770.0T patent/ES2566963T3/es active Active
- 2008-11-21 LT LT15189714T patent/LT3002298T/lt unknown
- 2008-11-21 DK DK08852770.0T patent/DK2222707T3/da active
-
2012
- 2012-04-13 US US13/446,320 patent/US8399648B2/en active Active
-
2013
- 2013-03-04 US US13/783,952 patent/US20130171144A1/en not_active Abandoned
-
2014
- 2014-04-01 US US14/242,692 patent/US9125895B2/en active Active
-
2015
- 2015-07-27 US US14/809,551 patent/US9636399B2/en active Active
-
2016
- 2016-09-29 HK HK16111374.5A patent/HK1223114A1/zh unknown
-
2017
- 2017-03-27 US US15/470,758 patent/US20170204195A1/en not_active Abandoned
-
2018
- 2018-07-30 US US16/049,141 patent/US10577428B2/en active Active
-
2019
- 2019-11-05 HR HRP20191999TT patent/HRP20191999T1/hr unknown
- 2019-11-06 CY CY20191101163T patent/CY1122270T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10577428B2 (en) | Anti-factor XI monoclonal antibodies and methods of use thereof | |
| KR102060376B1 (ko) | 응고 인자 xi 및/또는 그의 활성화 형태 인자 xia에 결합할 수 있는 항체 및 그의 용도 | |
| KR102042982B1 (ko) | 억제성 항-ｘｉｉ/ｘｉｉａ 인자 모노클로날 항체 및 이들의 사용 | |
| RU2758160C2 (ru) | Новые антитела против фактора xi и их применения | |
| JP2021527698A (ja) | 様々な血栓性の疾患および障害の治療のためのｍａｓｐ−２を阻害する組成物および方法 | |
| AU2021202612B2 (en) | Inhibition of platelet aggregation using anti-human GPVI antibodies | |
| AU2017265172B2 (en) | Anti-factor xi monoclonal antibodies and methods of use thereof | |
| US20170355771A1 (en) | Anti-gpiib/iiia antibodies and uses thereof | |
| AU2014202009A1 (en) | Anti-factor xi monoclonal antibodies and methods of use thereof | |
| JP7509787B2 (ja) | 抗血栓症作用および抗炎症作用を有する、第ｘｉ因子に対する新規ヒト化抗体およびその使用 | |
| OA20005A (en) | Compositions and methods of inhibiting MASP-2 for the treatment of various thrombotic diseases and disorders. | |
| NZ619385B2 (en) | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses | |
| TR201815476T4 (tr) | Koagülasyon Faktörü XI ve/veya bunun aktive formu faktör XIa'ya bağlanabilen antikorlar ve bunların kullanımları. |